Monocytes as regulators of inflammation and HIV-related comorbidities during cART

Joshua J Anzinger, Tiffany R Butterfield, Thomas A Angelovich, Suzanne Mary Crowe, Clovis Prince-Steve Palmer

Research output: Contribution to journalArticleResearchpeer-review

41 Citations (Scopus)

Abstract

Combined antiretroviral therapy (cART) extends the lifespan and the quality of life for HIV-infected persons but does not completely eliminate chronic immune activation and inflammation. The low level of chronic immune activation persisting during cART-treated HIV infection is associated with the development of diseases which usually occur in the elderly. Although T-cell activation has been extensively examined in the context of cART-treated HIV infection, monocyte activation is only beginning to be recognized as an important source of inflammation in this context. Here we examine markers and sources of monocyte activation during cART-treated HIV infection and discuss the role of monocytes during cardiovascular disease, HIV-associated neurocognitive disorder, and innate immune aging.
Original languageEnglish
Pages (from-to)1 - 11
Number of pages11
JournalJournal of Immunology Research
Volume2014
Issue numberArt. No.: 569819
DOIs
Publication statusPublished - 2014

Cite this

Anzinger, Joshua J ; Butterfield, Tiffany R ; Angelovich, Thomas A ; Crowe, Suzanne Mary ; Palmer, Clovis Prince-Steve. / Monocytes as regulators of inflammation and HIV-related comorbidities during cART. In: Journal of Immunology Research. 2014 ; Vol. 2014, No. Art. No.: 569819. pp. 1 - 11.
@article{146135263f1a419fb517a80a3cfcaf44,
title = "Monocytes as regulators of inflammation and HIV-related comorbidities during cART",
abstract = "Combined antiretroviral therapy (cART) extends the lifespan and the quality of life for HIV-infected persons but does not completely eliminate chronic immune activation and inflammation. The low level of chronic immune activation persisting during cART-treated HIV infection is associated with the development of diseases which usually occur in the elderly. Although T-cell activation has been extensively examined in the context of cART-treated HIV infection, monocyte activation is only beginning to be recognized as an important source of inflammation in this context. Here we examine markers and sources of monocyte activation during cART-treated HIV infection and discuss the role of monocytes during cardiovascular disease, HIV-associated neurocognitive disorder, and innate immune aging.",
author = "Anzinger, {Joshua J} and Butterfield, {Tiffany R} and Angelovich, {Thomas A} and Crowe, {Suzanne Mary} and Palmer, {Clovis Prince-Steve}",
year = "2014",
doi = "10.1155/2014/569819",
language = "English",
volume = "2014",
pages = "1 -- 11",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",
number = "Art. No.: 569819",

}

Monocytes as regulators of inflammation and HIV-related comorbidities during cART. / Anzinger, Joshua J; Butterfield, Tiffany R; Angelovich, Thomas A; Crowe, Suzanne Mary; Palmer, Clovis Prince-Steve.

In: Journal of Immunology Research, Vol. 2014, No. Art. No.: 569819, 2014, p. 1 - 11.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Monocytes as regulators of inflammation and HIV-related comorbidities during cART

AU - Anzinger, Joshua J

AU - Butterfield, Tiffany R

AU - Angelovich, Thomas A

AU - Crowe, Suzanne Mary

AU - Palmer, Clovis Prince-Steve

PY - 2014

Y1 - 2014

N2 - Combined antiretroviral therapy (cART) extends the lifespan and the quality of life for HIV-infected persons but does not completely eliminate chronic immune activation and inflammation. The low level of chronic immune activation persisting during cART-treated HIV infection is associated with the development of diseases which usually occur in the elderly. Although T-cell activation has been extensively examined in the context of cART-treated HIV infection, monocyte activation is only beginning to be recognized as an important source of inflammation in this context. Here we examine markers and sources of monocyte activation during cART-treated HIV infection and discuss the role of monocytes during cardiovascular disease, HIV-associated neurocognitive disorder, and innate immune aging.

AB - Combined antiretroviral therapy (cART) extends the lifespan and the quality of life for HIV-infected persons but does not completely eliminate chronic immune activation and inflammation. The low level of chronic immune activation persisting during cART-treated HIV infection is associated with the development of diseases which usually occur in the elderly. Although T-cell activation has been extensively examined in the context of cART-treated HIV infection, monocyte activation is only beginning to be recognized as an important source of inflammation in this context. Here we examine markers and sources of monocyte activation during cART-treated HIV infection and discuss the role of monocytes during cardiovascular disease, HIV-associated neurocognitive disorder, and innate immune aging.

UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082935/pdf/JIR2014-569819.pdf

U2 - 10.1155/2014/569819

DO - 10.1155/2014/569819

M3 - Article

VL - 2014

SP - 1

EP - 11

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

IS - Art. No.: 569819

ER -